CY1116423T1 - Ενωσεις δις(φθοροαλκυλο)-1,4-βενζοδιαζεπινονης - Google Patents
Ενωσεις δις(φθοροαλκυλο)-1,4-βενζοδιαζεπινονηςInfo
- Publication number
- CY1116423T1 CY1116423T1 CY20151100355T CY151100355T CY1116423T1 CY 1116423 T1 CY1116423 T1 CY 1116423T1 CY 20151100355 T CY20151100355 T CY 20151100355T CY 151100355 T CY151100355 T CY 151100355T CY 1116423 T1 CY1116423 T1 CY 1116423T1
- Authority
- CY
- Cyprus
- Prior art keywords
- compounds
- benzodiazepinone
- fluoroalkyl
- bis
- ch2ch2cf3
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 125000003709 fluoroalkyl group Chemical group 0.000 title 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000005650 Notch Receptors Human genes 0.000 abstract 1
- 108010070047 Notch Receptors Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
- C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
- C07D243/24—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161466238P | 2011-03-22 | 2011-03-22 | |
| EP12711102.9A EP2688873B1 (en) | 2011-03-22 | 2012-03-22 | Bis(fluoroalkyl)-1,4-benzodiazepinone compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1116423T1 true CY1116423T1 (el) | 2017-02-08 |
Family
ID=45894701
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20151100355T CY1116423T1 (el) | 2011-03-22 | 2015-04-17 | Ενωσεις δις(φθοροαλκυλο)-1,4-βενζοδιαζεπινονης |
Country Status (32)
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2488204T3 (en) | 2009-10-16 | 2016-06-06 | Oncomed Pharm Inc | Therapeutic combination and use of DLL4 antagonist antibodies and blood pressure lowering agents |
| SI3485903T1 (sl) | 2011-09-23 | 2023-02-28 | Mereo Biopharma 5, Inc. | Sredstva, ki vežejo VEGF/DLL4, in njihove uporabe |
| WO2014047369A1 (en) | 2012-09-21 | 2014-03-27 | Bristol-Myers Squibb Company | Substituted 1,5-benzodiazepinone compounds |
| EP2897938B1 (en) * | 2012-09-21 | 2017-03-15 | Bristol-Myers Squibb Company | Fluoroalkyl dibenzodiazepinone compounds |
| US9249157B2 (en) | 2012-09-21 | 2016-02-02 | Bristol-Myers Squibb Company | Tricyclic heterocycle compounds |
| US9427442B2 (en) | 2012-09-21 | 2016-08-30 | Bristol-Myers Squibb Company | Fluoroalkyl and fluorocycloalkyl 1,4-benzodiazepinone compounds |
| US9133139B2 (en) | 2012-09-21 | 2015-09-15 | Bristol-Myers Squibb Company | Fluoroalkyl-1,4-benzodiazepinone compounds |
| TWI614238B (zh) * | 2012-09-21 | 2018-02-11 | 必治妥美雅史谷比公司 | 雙（氟烷基）－１，４－苯并二氮呯酮化合物及其前藥 |
| EP2897947B1 (en) | 2012-09-21 | 2016-10-26 | Bristol-Myers Squibb Company | Alkyl, fluoroalkyl-1,4-benzodiazepinone compounds |
| EP2897946B1 (en) | 2012-09-21 | 2016-11-16 | Bristol-Myers Squibb Company | N-substituted bis(fluoroalkkyl)-1,4-benzodiazepinone compounds as notch inhibitors |
| JP2015531792A (ja) | 2012-09-21 | 2015-11-05 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | １，４−ベンゾジアゼピノン化合物のプロドラッグ |
| CA2889638A1 (en) | 2012-10-31 | 2014-05-08 | Oncomed Pharmaceuticals, Inc. | Methods and monitoring of treatment with a dll4 antagonist |
| US9492469B2 (en) | 2013-04-04 | 2016-11-15 | Bristol-Myers Squibb Company | Combination therapy for the treatment of proliferative diseases |
| CA2938626A1 (en) | 2013-07-26 | 2015-01-29 | John Rothman | Compositions to improve the therapeutic benefit of bisantrene |
| CN103435562B (zh) * | 2013-08-26 | 2016-02-24 | 华东理工大学 | 6-取代苯并二氮卓-2,4-二酮类化合物及其用途 |
| US10174015B2 (en) | 2014-10-31 | 2019-01-08 | Xiamen University | Substituted heterocyclic derivative, preparation method and use thereof |
| CN104352488B (zh) * | 2014-10-31 | 2016-08-31 | 厦门大学 | 一类取代杂环衍生物在制备治疗疼痛药物中的应用 |
| CN104356082B (zh) * | 2014-10-31 | 2016-07-13 | 厦门大学 | 一类取代杂环衍生物及其制备方法 |
| CA2966042A1 (en) * | 2014-10-31 | 2016-05-06 | Oncomed Pharmaceuticals, Inc. | Combination therapy for treatment of disease |
| CN104892532B (zh) * | 2015-05-20 | 2017-09-08 | 成都理工大学 | 手性3‑取代1,3,4,5‑四氢‑1,4‑苯二氮*‑2‑酮的合成工艺 |
| JP7112324B2 (ja) | 2015-07-22 | 2022-08-03 | エナンタ ファーマシューティカルズ インコーポレイテッド | Ｒｓｖ阻害剤としてのベンゾジアゼピン誘導体 |
| AU2016326609B2 (en) | 2015-09-23 | 2023-03-09 | Mereo Biopharma 5, Inc. | Methods and compositions for treatment of cancer |
| CN108699077B (zh) | 2016-01-15 | 2021-03-02 | 英安塔制药有限公司 | 作为rsv抑制剂的杂环化合物 |
| JP7158023B2 (ja) | 2016-03-15 | 2022-10-21 | オリソン ヘノミクス エセ． アー． | 固形腫瘍の治療における使用のための、ｌｓｄ１阻害剤の組合せ |
| WO2018152413A1 (en) | 2017-02-16 | 2018-08-23 | Enanta Pharmaceuticals, Inc. | Processes for the preparation of benzodiazepine derivatives |
| EP3615068A1 (en) | 2017-04-28 | 2020-03-04 | Novartis AG | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| EP3615055A1 (en) | 2017-04-28 | 2020-03-04 | Novartis AG | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
| WO2018226801A1 (en) | 2017-06-07 | 2018-12-13 | Enanta Pharmaceuticals, Inc. | Aryldiazepine derivatives as rsv inhibitors |
| US11091501B2 (en) | 2017-06-30 | 2021-08-17 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as RSV inhibitors |
| US10851115B2 (en) | 2017-06-30 | 2020-12-01 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as RSV inhibitors |
| ES2817910T3 (es) * | 2017-08-04 | 2021-04-08 | Alzheimur 2012 S L | Uso de un anticuerpo antipresenilina para la prevención y/o tratamiento del cáncer |
| KR102645995B1 (ko) | 2017-09-29 | 2024-03-11 | 이난타 파마슈티칼스, 인코포레이티드 | Rsv 억제제로서의 병용 약학 제제 |
| PL3703750T3 (pl) | 2017-11-01 | 2025-04-07 | Juno Therapeutics, Inc. | Chimeryczne receptory antygenowe specyficzne dla antygenu dojrzewania komórek b i kodujące polinukleotydy |
| WO2019090364A1 (en) | 2017-11-06 | 2019-05-09 | Juno Therapeutics, Inc. | Combination of a cell therapy and a gamma secretase inhibitor |
| MX394621B (es) * | 2017-11-13 | 2025-03-24 | Enanta Pharm Inc | Procesos para la resolucion de los derivados de la benzodiazepina-2-ona y de la benzoazepin-2-ona |
| US10647711B2 (en) | 2017-11-13 | 2020-05-12 | Enanta Pharmaceuticals, Inc. | Azepin-2-one derivatives as RSV inhibitors |
| US10975094B2 (en) | 2018-04-11 | 2021-04-13 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as RSV inhibitors |
| US20210379079A1 (en) * | 2018-05-06 | 2021-12-09 | Ayala Pharmaceuticals Inc. | Compositions comprising cd20 inhibitors and bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof |
| IL278492B2 (en) * | 2018-05-06 | 2025-03-01 | Ayala Pharmaceuticals Inc | Combination compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof |
| MX2020012253A (es) * | 2018-05-15 | 2021-01-29 | Ayala Pharmaceuticals Inc | Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiazepinona para el tratamiento del carcinoma quistico adenoide. |
| AU2019271151A1 (en) * | 2018-05-15 | 2021-01-07 | Ayala Pharmaceuticals Inc. | Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof |
| JP2021526517A (ja) * | 2018-05-24 | 2021-10-07 | アヤラ ファーマシューティカルズ インコーポレイテッド | ビスフルオロアルキル−１，４−ベンゾジアゼピノン化合物および免疫療法剤を含む組成物ならびにそれらの使用方法 |
| CN112384531B (zh) | 2018-06-01 | 2024-05-14 | 诺华股份有限公司 | 针对bcma的结合分子及其用途 |
| BR112021018335A2 (pt) | 2019-03-18 | 2021-11-23 | Enanta Pharm Inc | Derivados de benzodiazepina como inibidores de rsv |
| US11179400B2 (en) | 2019-04-09 | 2021-11-23 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as RSV inhibitors |
| JP2022533100A (ja) * | 2019-05-15 | 2022-07-21 | アヤラ ファーマシューティカルズ インコーポレイテッド | Ｎｏｔｃｈ活性化乳がんを治療するためのビスフルオロアルキル－１，４－ベンゾジアゼピノン化合物 |
| EP3986569A1 (en) | 2019-06-24 | 2022-04-27 | Novartis AG | Dosing regimen and combination therapies for multispecific antibodies targeting b-cell maturation antigen |
| MX2022003984A (es) | 2019-10-04 | 2022-07-27 | Enanta Pharm Inc | Compuestos heterociclicos antivirales. |
| US11505558B1 (en) | 2019-10-04 | 2022-11-22 | Enanta Pharmaceuticals, Inc. | Antiviral heterocyclic compounds |
| UY39032A (es) | 2020-01-24 | 2021-07-30 | Enanta Pharm Inc | Compuestos heterocíclicos como agentes antivirales |
| US11534439B2 (en) | 2020-07-07 | 2022-12-27 | Enanta Pharmaceuticals, Inc. | Dihydroquinoxaline and dihydropyridopyrazine derivatives as RSV inhibitors |
| MX2023002612A (es) | 2020-09-03 | 2023-05-16 | Bristol Myers Squibb Co | Polimorfos de compuestos de bis(fluoroalquilo)-1,4-benzodiazepinon a y usos de los mismos. |
| WO2022086840A1 (en) | 2020-10-19 | 2022-04-28 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as anti-viral agents |
| EP4008324A1 (en) | 2020-12-07 | 2022-06-08 | Cellestia Biotech AG | Combinations comprising an inhibitor of an anti-apoptotic protein, such as bcl-2, bcl-xl, bclw or mcl-1, and a notch signaling pathway inhibitor for treating cancer |
| EP4255409A1 (en) | 2020-12-07 | 2023-10-11 | Cellestia Biotech AG | Pharmaceutical combinations for treating cancer |
| WO2022182861A1 (en) | 2021-02-26 | 2022-09-01 | Enanta Pharmaceuticals, Inc. | Antiviral heterocyclic compounds |
| TW202313020A (zh) | 2021-06-02 | 2023-04-01 | 瑞士商西萊絲蒂亞生物科技股份有限公司 | 自體免疫及發炎性疾病的治療方法 |
| US20250000870A1 (en) | 2021-11-08 | 2025-01-02 | Cellestia Biotech Ag | Pharmaceutical Combinations for Treating Cancer |
| EP4223292A1 (en) | 2022-02-07 | 2023-08-09 | Cellestia Biotech AG | Pharmaceutical combinations for treating cancer |
| AR129003A1 (es) | 2022-04-07 | 2024-07-03 | Enanta Pharm Inc | Compuestos heterocíclicos antivirales |
| WO2023211997A1 (en) | 2022-04-27 | 2023-11-02 | Enanta Pharmaceuticals, Inc. | Antiviral compounds |
| CN120882691A (zh) * | 2022-12-28 | 2025-10-31 | 伊米若梅有限公司 | 用于制备双(氟烷基)苯并二氮杂䓬酮化合物的中间体盐 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5324726A (en) | 1989-12-18 | 1994-06-28 | Merck & Co., Inc. | Benzodiazepine analogs |
| EP0891337A1 (en) * | 1996-04-03 | 1999-01-20 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US5852010A (en) * | 1996-04-03 | 1998-12-22 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US6635632B1 (en) | 1996-12-23 | 2003-10-21 | Athena Neurosciences, Inc. | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
| NZ525513A (en) | 1998-08-07 | 2004-09-24 | Pont Pharmaceuticals Du | Succinoylamino lactams as inhibitors of Abeta protein production |
| HRP990246A2 (en) | 1998-08-07 | 2000-06-30 | Du Pont Pharm Co | Succinoylamino benzodiazepines as inhibitors of a beta protein production |
| US6737038B1 (en) | 1998-11-12 | 2004-05-18 | Bristol-Myers Squibb Company | Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging |
| US6331408B1 (en) | 1998-11-12 | 2001-12-18 | Robert Zaczek | Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production |
| IL142816A0 (en) * | 1998-12-24 | 2002-03-10 | Du Pont Pharm Co | SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF Aβ PROTEIN PRODUCTION |
| EP1143946B1 (en) | 1999-04-30 | 2004-01-28 | The Regents Of The University Of Michigan | Use of benzodiazepines for treating autoimmune diseases induced by apoptosis |
| US6960576B2 (en) | 1999-09-13 | 2005-11-01 | Bristol-Myers Squibb Pharma Company | Hydroxyalkanoylaminolactams and related structures as inhibitors of Aβ protein production |
| US6503902B2 (en) | 1999-09-13 | 2003-01-07 | Bristol-Myers Squibb Pharma Company | Hydroxyalkanoylaminolactams and related structures as inhibitors of a β protein production |
| WO2001027108A1 (en) | 1999-10-08 | 2001-04-19 | Bristol-Myers Squibb Pharma Company | AMINO LACTAM SULFONAMIDES AS INHIBITORS OF Aβ PROTEIN PRODUCTION |
| IL150524A0 (en) * | 2000-01-07 | 2003-02-12 | Transform Pharmaceuticals Inc | High-throughput formation, identification, and analysis of diverse solid-forms |
| EP1254108A1 (en) | 2000-01-24 | 2002-11-06 | MERCK SHARP & DOHME LTD. | Gamma-secretase inhibitors |
| EP1261610A2 (en) | 2000-02-17 | 2002-12-04 | Bristol-Myers Squibb Pharma Company | Succinoylamino carbocycles and heterocycles as inhibitors of a-beta protein production |
| US6495540B2 (en) | 2000-03-28 | 2002-12-17 | Bristol - Myers Squibb Pharma Company | Lactams as inhibitors of A-β protein production |
| CA2404314A1 (en) | 2000-03-31 | 2001-10-11 | Lorin Andrew Thompson | Succinoylamino heterocycles as inhibitors of a.beta. protein production |
| IL151576A0 (en) | 2000-04-03 | 2003-04-10 | Bristol Myers Squibb Pharma Co | Cyclic lactams as inhibitors of a-beta protein production |
| WO2001074784A1 (en) | 2000-04-03 | 2001-10-11 | Dupont Pharmaceuticals Company | CYCLIC LACTAMS AS INHIBITORS OF A-β PROTEIN PRODUCTION |
| GB0008710D0 (en) | 2000-04-07 | 2000-05-31 | Merck Sharp & Dohme | Therapeutic compounds |
| AU2001257006A1 (en) | 2000-04-11 | 2001-10-23 | Du Pont Pharmaceuticals Company | Substituted lactams as inhibitors of abeta protein production |
| AU2001261728A1 (en) | 2000-05-17 | 2001-11-26 | Bristol-Myers Squibb Pharma Company | Use of small molecule radioligands for diagnostic imaging |
| GB0012671D0 (en) | 2000-05-24 | 2000-07-19 | Merck Sharp & Dohme | Therapeutic agents |
| IL147629A0 (en) | 2000-06-01 | 2002-08-14 | Bristol Myers Squibb Pharma Co | LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Aβ PROTEIN PRODUCTION |
| US7001901B2 (en) | 2002-08-27 | 2006-02-21 | Bristol-Myers Squibb Company | Tetrazolylpropionamides as inhibitors of Aβ protein production |
| BR0314595A (pt) | 2002-09-20 | 2005-08-09 | Arrow Therapeutics Ltd | Uso de um derivado de benzodiazepina ou um sal farmaceuticamente aceitável deste, inalador ou nebulisador, produto, usos de um produto e de um composto ou sal farmaceuticamente aceitável deste, derivado de benzodiazepina, composto, e, composição farmacêutica |
| MXPA05008172A (es) | 2003-02-04 | 2005-10-05 | Hoffmann La Roche | Derivados de malonamida como inhibidores gamma-secretasa. |
| GB0312365D0 (en) | 2003-05-30 | 2003-07-02 | Univ Aston | Novel 3-substituted-1, 4-benzodiazepines |
| KR20070087233A (ko) | 2003-09-09 | 2007-08-27 | 에프. 호프만-라 로슈 아게 | 감마-세크리테이즈의 활성을 차단하는 말론아미드 유도체 |
| EP1795198A1 (en) | 2005-12-09 | 2007-06-13 | Hubrecht Laboratorium | Treatment of Barret's esophagus |
| WO2007100895A2 (en) | 2006-02-27 | 2007-09-07 | The Johns Hopkins University | Cancer treatment with gamma-secretase inhibitors |
| CA2645756C (en) | 2006-03-27 | 2013-12-31 | F. Hoffmann-La Roche Ag | Malonamide derivatives as gamma secretase inhibitors |
| MX2009002538A (es) | 2006-09-20 | 2009-03-20 | Hoffmann La Roche | Derivados de 4-oxo-2,3,4,5-tetrahidro-benzo[b][1,4]diazepina. |
| KR101136260B1 (ko) | 2007-08-14 | 2012-04-19 | 일라이 릴리 앤드 캄파니 | 감마-세크레타제 억제제로서의 아제핀 유도체 |
| KR20140007979A (ko) | 2008-01-11 | 2014-01-20 | 에프. 호프만-라 로슈 아게 | 암 치료를 위한 감마-세크레타제 저해제의 용도 |
| WO2011060051A1 (en) | 2009-11-12 | 2011-05-19 | University Of Massachusetts | Methods for treating glioblastoma |
| US20120225860A1 (en) | 2011-03-02 | 2012-09-06 | John Frederick Boylan | Method for administration of a gamma secretase inhibitor |
-
2012
- 2012-02-24 TW TW101106426A patent/TWI530489B/zh active
- 2012-03-21 AR ARP120100932A patent/AR085471A1/es not_active Application Discontinuation
- 2012-03-21 UY UY0001033961A patent/UY33961A/es active IP Right Grant
- 2012-03-22 SI SI201230162T patent/SI2688873T1/sl unknown
- 2012-03-22 CA CA2830902A patent/CA2830902C/en active Active
- 2012-03-22 KR KR1020137027347A patent/KR101948347B1/ko active Active
- 2012-03-22 WO PCT/US2012/030021 patent/WO2012129353A1/en not_active Ceased
- 2012-03-22 DK DK12711102T patent/DK2688873T3/en active
- 2012-03-22 CN CN201280025022.2A patent/CN103717576B/zh active Active
- 2012-03-22 SG SG2013070743A patent/SG193555A1/en unknown
- 2012-03-22 MX MX2013010420A patent/MX2013010420A/es active IP Right Grant
- 2012-03-22 RS RS20150150A patent/RS53843B1/sr unknown
- 2012-03-22 US US13/426,730 patent/US8629136B2/en active Active
- 2012-03-22 AU AU2012230904A patent/AU2012230904B2/en active Active
- 2012-03-22 PH PH1/2013/501738A patent/PH12013501738B1/en unknown
- 2012-03-22 MA MA36323A patent/MA35036B1/fr unknown
- 2012-03-22 EP EP12711102.9A patent/EP2688873B1/en active Active
- 2012-03-22 JP JP2014501220A patent/JP5873923B2/ja active Active
- 2012-03-22 MY MYPI2013003410A patent/MY161233A/en unknown
- 2012-03-22 PL PL12711102T patent/PL2688873T3/pl unknown
- 2012-03-22 HR HRP20150273TT patent/HRP20150273T1/hr unknown
- 2012-03-22 BR BR112013024059-8A patent/BR112013024059B1/pt active IP Right Grant
- 2012-03-22 EA EA201391324A patent/EA022530B1/ru not_active IP Right Cessation
- 2012-03-22 ES ES12711102.9T patent/ES2534080T3/es active Active
- 2012-03-22 PT PT127111029T patent/PT2688873E/pt unknown
- 2012-03-22 PE PE2013002083A patent/PE20140626A1/es active IP Right Grant
-
2013
- 2013-09-17 IL IL228534A patent/IL228534A/en active IP Right Grant
- 2013-09-17 CL CL2013002690A patent/CL2013002690A1/es unknown
- 2013-09-19 TN TNP2013000372A patent/TN2013000372A1/fr unknown
- 2013-09-20 CO CO13224494A patent/CO6771446A2/es unknown
- 2013-12-09 US US14/100,896 patent/US8822454B2/en active Active
-
2015
- 2015-04-13 SM SM201500091T patent/SMT201500091B/xx unknown
- 2015-04-17 CY CY20151100355T patent/CY1116423T1/el unknown
-
2023
- 2023-07-07 AR ARP230101776A patent/AR129859A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1116423T1 (el) | Ενωσεις δις(φθοροαλκυλο)-1,4-βενζοδιαζεπινονης | |
| CY1118739T1 (el) | Ενωσεις αμφι(φθoρoαλκυλ)-1,4-βενζoδιαζεπινoνης ως αναστολεις toy notch | |
| CY1120104T1 (el) | Αναστολεις της syk | |
| CY1123756T1 (el) | Παραγωγα διπυραζολιου ως αναστολεις jak | |
| CY1122611T1 (el) | Ενωσεις πυραζολοπυριμιδινης ως αναστολεις κινασης | |
| CY1122610T1 (el) | Αλκοξυ πυραζολια ως ενεργοποιητες διαλυτης γουανυλικης κυκλασης | |
| CY1119939T1 (el) | Παραγωγα 2,3-διϋδρο-βενζο[1,4]οξαζιν και σχετικες ενωσεις οπως αναστολεις φωσφοϊνοσιτινης-3 κινασης (ρι3κ) για τη θεραπεια παραδειγματος χαρην της ρευματοειδους αρθριτιδας | |
| CY1118340T1 (el) | Αναστολεις κινασης | |
| PE20151601A1 (es) | Compuestos novedosos de pirimidina y piridina y su uso | |
| CY1121357T1 (el) | Νεος ανοσοτροποποιητης και αντιφλεγμονωδεις ενωσεις | |
| CY1118610T1 (el) | Αναστολεις κινασεων και η χρηση τους στη θεραπευτικη αγωγη του καρκινου | |
| CY1119387T1 (el) | Τριαζολοπυραζινες ως αναστολεις brd4 για χρηση στην αντιμετωπιση καρκινου | |
| CR20140548A (es) | Derivados de aril-sultamo como moduladores de rorc | |
| CY1117776T1 (el) | Εναντιομερη ενωσεων σπειρο-οξινδολιου και οι χρησεις τους ως θεραπευτικοι παραγοντες | |
| CY1118379T1 (el) | Αναστολεις ιου ηπατιτιδας c | |
| UY31545A1 (es) | Nuevos derivados de 2-carboxamida cianoaminourea, sus sales y profarmacos farmacéuticamente aceptables, procesos de preparacion y aplicaciones | |
| CY1119620T1 (el) | Αναστολεις νεπριλυσινης | |
| UY33921A (es) | Oxazinopteridinas y oxazinoptiridinonas n-sustituidas | |
| DOP2019000204A (es) | Dendrímeros terapéuticos | |
| DOP2016000276A (es) | 2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS | |
| CY1114140T1 (el) | Ενωσεις 4-πυριδινονης και η χρηση αυτων για τον καρκινο | |
| CR20150056A (es) | Derivados de azaindol | |
| CY1122744T1 (el) | Ενωσεις τετρακυκλινης | |
| CY1116173T1 (el) | Ετεροαρυλικες ενωσεις ως υποκαταστατες 5-ητ4 υποδοχεων | |
| CO6321280A2 (es) | Nueva clase espiro piperidinas para el tratamiento de enfermedades neurodegenerativas |